Silymarin in COVID-19 Pneumonia

• Status: Recruiting
• Trial end date: 2021-02-28
• Target enrollment: 0
• Participant gender: All

Summary

A randomized placebo controlled trial to assess the clinical outcome in COVID-19 Pneumonia following administration of Silymarin owing to its role as a p38 MAPK pathway inhibitor and its antiviral, anti-inflammatory and anti-oxidant effects

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Silymarin

Criteria

Inclusion Criteria:

• COVID-19 patients with CT Chest-proven viral pneumonia with any degree of severity.

Exclusion Criteria:

• Patients < 18 years of age.

• Patients with mild symptoms (as per WHO criteria) of SARS-CoV-2